Abstract
The objective was to determine whether plasma-derived hepatitis B vaccine is immunogenic in preterm appropriate for gestation babies when administered at birth and to compare the immunogenicity between 5 μg and 10 μg doses of the vaccine in these babies.
Fifty preterm neonates (31-36 weeks gestation) were randomized to receive 5 μg or 10 μg doses of plasma-derived hepatitis B vaccine at birth, with subsequent doses 1 and 6 months later. Serum specimens were obtained a month after each dose of the vaccine and were tested for antibody to hepatitis B surface antigen (anti-HBs).
Thirty six babies (gestation 31–36 weeks), 18 from each group competed the study. While 89.2% of the babies seroconverted, 82. 1% achieved seroprotective titres of anti-HBS (> 10 mlU/ml). There was no difference between weight, gestational age, age of administration of vaccine and age of estimation of anti-HBs between 5 μg and 10 μg groups. The difference in the seroprotective rates were not statistically different between the groups (5 μg 78.5%; 10 μg-85.7%).
Although immune response to plasma derived hepatitis B vaccine in preterm babies is suboptimal when the first dose is administered at birth, the full course achieves adequate seroprotective levels.
Similar content being viewed by others
References
Nayak NC, Panda SK, Zukerman AJ, Bhan MK, Guha DK. Dynamics and impact of perinatal transmission in North India.Indian J Med Virol 1987; 21:137–145.
Panda SK, Ramesh R, Rao KVS, Gupta A, Zuckerman AJ, Nayak NC. Comparative evaluation of the immunogenicity of yeast-derived (recombinant) and plasma derived hepatitis vaccine in infants.J Med Virol 1991; 35: 297–302.
Committee on Infectious Diseases. American Academy of Pediatrics, Universal Hepatitis B immunization.Pediatrics 1992; 89: 795–800.
Hadler SC, Margolis HS. Hepatitis B Immunization: Vaccine types, efficacy and indication for immunization.Curr Clin Top Infect Dis 1992; 12:282–308.
Jilg W, Lorbeer B, Schmidt Met al. Clinical evaluation of recombinant Hepatitis B vaccine.Lancet 1984; 2: 1174–5.
Andre IE. Overview of 5 year experience with yeast derived Hepatitis B vaccine.Vaccine 1990; 8:574–8.
American Academy of Pediatrics. Report of the Committees on Infectious Diseases. Elk Grove Village. Illinois.AAP 1991; 238–55.
Maynard P, Barin F, Chiron JPet al. Efficacy of Hepatitis B vaccine in prevention of early HBsAg carrier state in children.Lancet 1981; 1:289–292.
Del Canho R, Grosheide PM, Geraerbs LJ, Heijtink RA, Scahalm SW. Hepatitis B vaccination and preterm infants.Pediatr Inf Dis J 1993; 12:407–8.
Charareewong S, Jiraponsa A, Lokaphadhare K. Immune response to Hepatitis B vaccine in premature neonate.South East Asian J Med Publ Hith 1991; 22: 39–40.
Yu Lung Lau, Tam AYC, Ng KW, Tsoi NS, Lam B, Lamp Pet al. Response of preterm infants to hepatitis B vaccine.J Pediatr 1992; 121:962–65.
Patel DM, Butter RN. Feldman Set al. Immunogenicity of Hepatitis B vaccine in healthy very low birth weight infants.Pediatrics 1997; 131:641–643.
Kim SC, Chung EK, Alodinka RLet al. Immunogenicity of Hepatitis B vaccine in preterm infants.Pediatrics 1997; 99:534–536.
Huang FY, Lee PI, Lee CYet al. Hepatitis B vaccination in preterm infants.Arch Dis Child 1997; 77: F135–138.
Chirco G. Belloni C. Gasparoni A, Cerbo RM, Rondini G, Klersyet al. Hepatitis B immunization in infants of Hepatitis B surface antigen negative mothers.Pediatrics 1993; 92:717–19.
Jayanthi S, Narang A, Dhiman RK, Kumar P. Seroconversion after Hepatitis B vaccine in preterm and small for gestational age babies. M.D. thesis submitted to PGIMER, Chandigarh, December 1997.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shankar, K.R., Dhiman, R.K. & Narang, A. Immunogenicity of plasma-derived Hepatitis B vaccine in preterm infants. Indian J Pediatr 67, 23–26 (2000). https://doi.org/10.1007/BF02802630
Issue Date:
DOI: https://doi.org/10.1007/BF02802630